Oppenheimer started coverage on shares of BeyondAirInc . (NASDAQ:XAIR) in a report issued on Tuesday, Briefing.com Automated Import reports. The firm set an “outperform” rating and a $9.00 price target on the stock. Oppenheimer’s price target would suggest a potential upside of 106.42% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut BeyondAirInc . from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine cut BeyondAirInc . from a “buy” rating to a “hold” rating in a research report on Monday.
NASDAQ:XAIR opened at $4.36 on Tuesday. BeyondAirInc . has a 52 week low of $3.11 and a 52 week high of $6.25. The firm has a market cap of $48.35 million, a PE ratio of -5.19 and a beta of -0.27. The company’s 50-day simple moving average is $4.68.
About BeyondAirInc .
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Featured Article: Market Capitalization
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.